Enlivex Therapeutics Ltd.
Clinical-stage company developing Allocetra, an allogeneic cell therapy intended to reprogram macrophages toward immune homeostasis. Company-reported development includes an FDA Regenerative Medicine Advanced Therapy designation in knee osteoarthritis.
Longevity thesis
If restoring macrophage homeostasis modifies age-related inflammatory disease, a single immune-directed cell therapy could apply across several inflammaging indications.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Allocetra | Phase 2b | Knee osteoarthritis |
Recent developments
- 13 Jul 2026Company reported FDA RMAT designation for Allocetra in age-related knee osteoarthritis.
Scientific evidence
Company-reported only. LONGEFI holds no independent Evidence Record for Allocetra; regulatory designation is not efficacy.
LONGEFI analysis
LONGEFI treats Enlivex as an inflammaging read-through: the designation is a regulatory milestone, not a clinical outcome. Curated profile depth is deliberately minimal until independently verifiable material exists.
Analysis is research commentary. It is not investment advice or a recommendation.